Vitamin D Receptor Polymorphism and Breast Cancer Risk: A Meta-Analysis - PubMed (original) (raw)

Meta-Analysis

Vitamin D Receptor Polymorphism and Breast Cancer Risk: A Meta-Analysis

Demin Lu et al. Medicine (Baltimore). 2016 May.

Abstract

The objective was to perform a meta-analysis to summarize the available evidence from prospective nested case-control studies on the association of vitamin D receptor (VDR) polymorphism and the risk of breast cancer.We searched PubMed, ISI web of science, EMBASE, and reference lists for included articles. Study specific odds ratios (ORs) and 95% confidence intervals (CIs) were pooled by using fixed-effect or random-effects models.Eight studies were included in the meta-analysis. There were no association between Fok1 gene allele contrast f versus F (OR: 0.859; 95%CI: 0.685-1.079), ff versus FF (OR: 0.893; 95%CI: 0.763-1.045), recessive models ff versus FF+Ff (OR: 0.932; 95%CI: 0.796-1.092), and dominant models ff+Ff versus FF (OR: 0.899; 95%CI: 0.780-1.037). The estimated VDR polymorphism showed no significant association between Bsm1, Taq1, Apa1 polymorphism, and breast cancer risk. In the Caucasian ethnic subgroup, no association was found between allele contrast, recessive models, and dominant models on Fok1, Bsm1 polymorphism, and breast cancer risk.VDR polymorphism (Fok1, Bsm1, Taq1, and Apa1) were not associated with the risk of breast cancer in the general population as well as Caucasian population.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

FIGURE 1

Flowchart of selection of studies for inclusion in the meta-analysis.

FIGURE 2

Forest plot and summary OR of the association between VDR Fok1 polymorphism and breast cancer risk. (A) Allele model (f vs F). (B) Homozygote model (ff vs FF). (C) Recessive models (ff vs FF+Ff). (D) Dominant models (ff+Ff vs FF). VDR = vitamin D receptor.

Cited by

Vitamin D in Cancer Prevention and Treatment: A Review of Epidemiological, Preclinical, and Cellular Studies.
Dallavalasa S, Tulimilli SV, Bettada VG, Karnik M, Uthaiah CA, Anantharaju PG, Nataraj SM, Ramashetty R, Sukocheva OA, Tse E, Salimath PV, Madhunapantula SV. Dallavalasa S, et al. Cancers (Basel). 2024 Sep 20;16(18):3211. doi: 10.3390/cancers16183211. Cancers (Basel). 2024. PMID: 39335182 Free PMC article. Review.
Vitamin D receptor gene polymorphisms and risk of breast cancer in Iranian women.
Kazemi SM, Esmaieli-Bandboni A, Veisi Malekshahi Z, Shahbaz Sardood M, Hashemi M, Majidzadeh K, Kadkhodazadeh M, Esmaili R, Negahdari B. Kazemi SM, et al. Ann Med Surg (Lond). 2021 Dec 4;73:103150. doi: 10.1016/j.amsu.2021.103150. eCollection 2022 Jan. Ann Med Surg (Lond). 2021. PMID: 34917354 Free PMC article.
Assessment the effect of vitamin D supplementation on plasma vitamin D levels, inflammation, and oxidative stress biomarkers based on vitamin D receptor genetic variation in breast cancer survivors: a protocol for clinical trial.
Kazemian E, Akbari ME, Moradi N, Gharibzadeh S, Amouzegar A, Rozek LS, Mondul AM, Khademolmele M, Zarins KR, Ghodoosi N, Shateri Z, Fallah S, Davoodi SH. Kazemian E, et al. J Health Popul Nutr. 2021 Nov 2;40(1):46. doi: 10.1186/s41043-021-00272-9. J Health Popul Nutr. 2021. PMID: 34727991 Free PMC article.
Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis.
Xu H, Liu Z, Shi H, Wang C. Xu H, et al. BMC Cancer. 2020 Nov 1;20(1):1051. doi: 10.1186/s12885-020-07559-w. BMC Cancer. 2020. PMID: 33131491 Free PMC article.
Vitamin D in Triple-Negative and BRCA1-Deficient Breast Cancer-Implications for Pathogenesis and Therapy.
Blasiak J, Pawlowska E, Chojnacki J, Szczepanska J, Fila M, Chojnacki C. Blasiak J, et al. Int J Mol Sci. 2020 May 23;21(10):3670. doi: 10.3390/ijms21103670. Int J Mol Sci. 2020. PMID: 32456160 Free PMC article. Review.

References

1. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006; 56:168–183. - PubMed
1. Nelson HD, Zakher B, Cantor A, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med 2012; 156:635–648. - PMC - PubMed
1. Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med 2010; 362:986–993. - PMC - PubMed
1. Goodwin PJ, Ennis M, Pritchard KI, et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009; 27:3757–3763. - PubMed
1. McCullough ML, Bostick RM, Mayo TL. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 2009; 29:111–132. - PubMed

Vitamin D Receptor Polymorphism and Breast Cancer Risk: A Meta-Analysis - PubMed (original) (raw)